ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Pasithea Therapeutics Corporation

Pasithea Therapeutics Corporation (KTTA)

5.80
-0.05
(-0.85%)
Closed July 23 4:00PM
5.80
0.00
(0.00%)
After Hours: 4:06PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
5.80
Bid
4.75
Ask
7.29
Volume
4,606
5.50 Day's Range 6.06
4.69 52 Week Range 17.40
Market Cap
Previous Close
5.85
Open
5.86
Last Trade
1
@
5.56
Last Trade Time
Financial Volume
$ 26,652
VWAP
5.7864
Average Volume (3m)
3,775
Shares Outstanding
1,043,248
Dividend Yield
-
PE Ratio
-0.38
Earnings Per Share (EPS)
-15.3
Revenue
-
Net Profit
-15.96M

About Pasithea Therapeutics Corporation

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly tre... Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
1970
Pasithea Therapeutics Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KTTA. The last closing price for Pasithea Therapeutics was $5.85. Over the last year, Pasithea Therapeutics shares have traded in a share price range of $ 4.69 to $ 17.40.

Pasithea Therapeutics currently has 1,043,248 shares outstanding. The market capitalization of Pasithea Therapeutics is $6.10 million. Pasithea Therapeutics has a price to earnings ratio (PE ratio) of -0.38.

KTTA Latest News

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and...

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company...

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

SOUTH SAN FRANCISCO, Calif. and MIAMI, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company...

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.356.422018348625.456.44415.4556956.00859792CS
41.1123.66737739874.696.44414.6937895.57300103CS
12-1.06-15.45189504376.867.694.6937755.69068319CS
26-1.16-16.66666666676.969.254.6943066.58487389CS
52-6.332-52.192548631712.13217.44.694592768.83727294CS
156-74.2-92.75801704.6992898356.60752381CS
260-74.2-92.75801704.6992898356.60752381CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.15M
CMAXCareMax Inc
$ 5.19
(228.48%)
102.64M
NUKKNukkleus Inc
$ 0.499
(55.94%)
26.2M
SNOASonoma Pharmaceuticals Inc
$ 0.423
(37.34%)
4.88M
ONDSOndas Holdings Inc
$ 1.1297
(34.06%)
2.19M
CGBSCrown LNG Holdings Ltd
$ 0.9902
(-29.77%)
3.29M
LGCBLinkage Global Inc
$ 3.7833
(-27.45%)
166.7k
SPECSpectaire Holdings Inc
$ 0.395
(-24.76%)
1.78M
GSUNGolden Sun Health Technology Group Ltd
$ 5.07
(-24.55%)
155.37k
SLNASelina Hospitality PLC
$ 0.0364
(-23.04%)
75.77M
NVDANVIDIA Corporation
$ 123.45
(4.68%)
221.22M
SQQQProShares UltraPro Short QQQ
$ 8.08
(-4.49%)
176.65M
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
151.42M
SERVServe Robotics Inc
$ 8.7192
(15.49%)
148.59M
NCPLNetcapital Inc
$ 0.1105
(6.25%)
121.97M

KTTA Discussion

View Posts
PennyStockTrader2 PennyStockTrader2 6 days ago
shocked at how low this has gone but I stepped up to buy, now we could possibly have bottomed. very bullish here
👍️0
PennyStockTrader2 PennyStockTrader2 4 weeks ago
continuing to add to my position, this should be a real winner
👍️0
PennyStockTrader2 PennyStockTrader2 2 months ago
added more up over 1000 shares accumulated. I believe we have something good here just need the right news, but the price is cheap.
👍️0
PennyStockTrader2 PennyStockTrader2 3 months ago
did end up making a little $ on KTTA, now my buddy has been pressuring me bigtime to buy as he believes the upside is just huge. Well finally cash freed up to the degree where I felt comfortable taking a position as it has pulled back, and i have an accumulated position of 500 shares around 7 bucks. This better move. or so help me. In any case, its a reasonable entry point here all the way down to 6 dollars (or below but I dont expect that).

Last check they have 16 mill in the bank which will could last them through end of this year.
👍️0
Invest-in-America Invest-in-America 7 months ago
Nope, Bro. (But THANKS for heads-up on it right now.)
👍️0
TIMGZ TIMGZ 7 months ago
DID YOU GRAB SOME BCNN ***OTC**** EARLIER TODAY
👍️0
Invest-in-America Invest-in-America 7 months ago
Indeed it was!! (I was simple much too LATE to the party.)
👍️0
TIMGZ TIMGZ 7 months ago
IF TRUMP WINS, WHAT DO YOU THING ABOUT THIS****

White House Says President Biden Will Make Clear To Ukraine's Zelenskyy That U.S. Standing Firm On Additional Funding Request
👍️0
TIMGZ TIMGZ 7 months ago
NEWS WAS OUT AT 801AM, ANYTHING AFTER 30% LIKE tw0122,****PLANNING TO EXIT** 100% START WATCHING LIKE AN OWL TO EXIT GRACIOUSLY. THAT WAS BEAUTIFUL RALLY FOR SUCH A PR
👍️0
Invest-in-America Invest-in-America 7 months ago
KTTA: Down the toilet. (I got suckered!!) Maybe later it goes back UP.
👍️0
TIMGZ TIMGZ 7 months ago
YOU ARE VERY OBSERVANT MY FRIEND*****JUST BUY FEW AND WAIT ***HOPEFULLY THE ALGO PICK ON THOSE SELECTION.


SOMETIMES AND MOST TIMES, MARKET IS TIMING BUT VERY HARD TO GET IT RIGHT. WE JUST CONTINUE TO LEARN
👍️0
Invest-in-America Invest-in-America 7 months ago
KTTA: YEP!! (I hate those stocks that run-up hard 30-days AFTER they got a low-price warning from the NASDAQ, & nothing else to support such a run-up --- e.g., today's @IONM & @NXTP. Can we PLEASE get a stock that runs-up hard behind some SUBSTANTIVE NEWS????)
👍️0
TIMGZ TIMGZ 7 months ago
THE MARKET IS WEIRD, AS LONG AS THE RALLY IS STARTED BIG***THE PR WAS A START****BUT NOT THIS RALLY. EVEN LOOK AT NXTP, IT RALLIED BIG**

WELCOME TO THE NEW NORM, AS LONG NO ONE IS LATE TO THE RALLY
👍️0
Invest-in-America Invest-in-America 7 months ago
KTTA: First of all, I GRABBED some of this, & still hold it. (The negative issue is the techno-jargon manner by which they cleverly VEILED the mere 'test tube' and/or 'petri dish' stage of their research regarding the drug in question.)
👍️0
madras50 madras50 7 months ago
what is so negative about it?
👍️0
Invest-in-America Invest-in-America 7 months ago
KTTA: Despite my negative opinions about their PR, this may nevertheless have a circa 400%-500% RUN UP today.
👍️0
OmegaMoney29 OmegaMoney29 7 months ago
Took 167 k from awls crew this am. Thanks 🙏
👍️0
OmegaMoney29 OmegaMoney29 7 months ago
Made 167k in the last hour while you’re posting why I don’t know. Ur followers must be stupid honestly
👍️0
Awl416 Awl416 7 months ago
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
👍️0
AJ Freely AJ Freely 1 year ago
$KTTA - Up 21% Pre-Market/ Current Price $0.47
Announces Intention to Commence a $4m Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
👍️0
m0n m0n 1 year ago
KTTA swinging for the fences here
👍️0
The Night Stalker The Night Stalker 1 year ago
as always the gay offerings are everyday common practice with big board biotechs,, always sold at loss on offerings, best to double up on the wedge,.
👍️0
The Night Stalker The Night Stalker 1 year ago
as always the gay offerings are everyday common practice with big board biotechs,, always sold at loss on offerings, best to double up on the wedge,.
👍️0
Zorro Zorro 1 year ago
Always the waiting game. Patience can pay if you know when to hold. Sometimes even when you get stuck. Love when the dead ones come to life. Lol!
👍️0
The Night Stalker The Night Stalker 1 year ago
best to buy them on the wedge with forward milestone events with volume spikes.

im in DRMA averaged down in the wedge pattern. we await for milestone events in coming weeks
👍️0
Zorro Zorro 1 year ago
Bottoms in here?
👍️0
The Night Stalker The Night Stalker 1 year ago
whats new
👍️0
The Night Stalker The Night Stalker 1 year ago
whats new
👍️0
PennyStockTrader2 PennyStockTrader2 1 year ago
been accumulating KTTA for months now only to see it go down to the low thirties, so todays news was a nice opportunity to sell a little with a GTC order on the open, you never know when these things can happen. This offer from Lucy Scientific Discovery is laughable and in the very least has brought eyes on KTTA so that its real value can start to be realized.
👍️0
Zorro Zorro 2 years ago
*Pasithea Therapeutics Investor Camac Partners Reported Purchase of 155,773 Shares @ Avg Price of $1.21/Share in Form 4 Filing on Thursday
Benzinga
👍️0
subslover subslover 2 years ago
MIAMI BEACH, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced it will present the preclinical proof of concept study results of its tolerizing vaccine program in multiple sclerosis (“MS”) on August 30th at the international conference “From Laboratory to Clinic: Medicine after COVID” held at Trinity College, Oxford University, United Kingdom.



From Laboratory to Clinic is an annual translational research conference established in 1984 that brings together basic scientists, clinicians, and industry researchers to explore how the latest discoveries in immunology and molecular medicine can be applied to improve clinical medicine. During the Symposium, Pasithea’s Chairman, National Academy of Sciences Professor Lawrence Steinman, will be giving the opening keynote lecture. Other speakers will include Dr. Carola Vinuesa, Professor at the Francis Crick Institute in London; Dr. Gali Alter, Professor of medicine at Harvard Medical School; Dr. Jeffrey Ravetch, Professor and head of the Laboratory of Molecular Genetics and Immunology at the Rockefeller University and Dr. Anne Schaefer, Vice-chair of Neuroscience at the Icahn School of Medicine at Mount Sinai.

“We look forward to presenting our data at this important international conference alongside other world recognized leading authorities in immunology and immunotherapy. The study results support the Company’s commitment to the program and move us further along our path to uncover new and effective treatments for neurological disorders,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.
👍️0
$treet $inatra $treet $inatra 2 years ago
great volume day yesterday on that news
👍️0
Hercules1 Hercules1 2 years ago
what does their balance sheet look like?

how much cash do they have?
👍️0
subslover subslover 2 years ago
Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis
August 11 2022 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for psychiatric and neurological disorders, today announced positive results from a preclinical proof of concept study of PAS002, its tolerizing vaccine program in multiple sclerosis (“MS”).
Earlier this year, a study in Nature, the world's leading science journal, showed that a molecule called GlialCAM found in the brain’s white matter is attacked in MS. GlialCAM shares a component of its protein structure that mimics an identical component of the Epstein Barr Virus (“EBV”) Nuclear Antigen-1, which plays a critical role in triggering MS.

In this proof of concept study, relapsing paralysis was established in a mouse model of relapsing-remitting experimental autoimmune encephalomyelitis (“EAE”), the standard animal model of MS. In three groups, a proprietary DNA cassette was engineered to encode GlialCAM and injected to potentially block acute disease and its relapse. These DNA molecules were designed to protect against paralytic disease by tolerizing the immune system so it would not attack myelin in the brain and spinal cord. The engineered DNA molecule creates tolerance, working like an ‘inverse vaccine’, and was administered intra-muscularly at days 0, 3, 7, 10, and 14. The study had a standard duration of 32 days.

The data showed that the engineered DNA plasmids provide a high level of efficacy in reducing disease severity and incidence of relapse when administered prophylactically in the EAE model, a widely used relapsing-remitting model of MS.

Key findings from the study include:

treatment with a DNA tolerizing ‘inverse vaccine’ delayed the onset of paralysis when compared to vehicle (p<0.001);
a statistically significant reduction in disease severity, when compared to vehicle (p=0.002);
a statistically significant reduction in relapse severity, when compared to vehicle (p<0.001);
treatment with a DNA vaccine prevented disease in approximately 50% of the mice, when compared to vehicle (p=0.004).
The study was conducted at Hooke Laboratories, an independent full-service Contract Research Organization with deep experience in the EAE animal model of MS.

“The results of this study show that this technology has the potential to tolerize to GlialCAM, a myelin molecule that has molecular similarity to the Epstein Barr Virus that triggers MS,” stated Pasithea’s Chairman, National Academy of Sciences Professor Lawrence Steinman, a world recognized leading authority in MS. Prof. Steinman’s research led to the development of the drug Tysabri, which is approved to treat patients with MS and Crohn's disease. “Remarkably, the piece of GlialCAM protein shared between EBV and white matter in the brain is also found in the pox viruses, including monkeypox. Monkeypox is rarely associated with brain inflammation, and this new technology may prove useful as a treatment for brain inflammation caused in certain viral infections.”

Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea, stated, "We’re thrilled with the strong preclinical efficacy data shown in this study. Although early stage, we believe these results demonstrate the promise and validity of our tolerizing approach, which is built on recent data on the biological mechanism linking infection with EBV with the development of MS. We have filed a provisional patent application and we will continue to rapidly pursue the PAS002 drug development program.”

The Company plans to present data from this study, including histology data and plasma inflammatory markers, in future major international conferences, and also to submit full data for peer-review publication.

About Multiple Sclerosis

Multiple Sclerosis (“MS”) is a chronic and potentially disabling autoimmune disease, and the most common neurodegenerative disease of the central nervous system in young adults. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, with the immune system attacking the myelin sheath that normally protects nerve fibers in the brain, spinal cord, and optic nerve. There are now 2.8 million people worldwide who have MS, and every five minutes, someone, somewhere in the world is diagnosed with this disorder. While there is no way to predict with any certainty how an individual’s disease will progress, four basic MS disease courses (also called types or phenotypes) have been defined: clinically isolated syndrome, relapsing remitting, secondary progressive and primary progressive. The most common affecting around 85 per cent of everyone diagnosed with MS is relapsing remitting MS (RRMS). It means that symptoms appear (a relapse), and then fade away, either partially or completely (remitting).

ABOUT PAS002

PAS002 is an engineered DNA plasmid designed to tolerize the immune system to GlialCAM.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the discovery, research and development of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
👍️0
$treet $inatra $treet $inatra 2 years ago
https://finance.yahoo.com/news/pasithea-therapeutics-announces-financial-business-201500938.html

-- Cash Balance of $52.9 million to fund operations well into 2024 --
-- Initiation of a drug development program in schizophrenia --
-- Initiation of a drug development program in multiple sclerosis --
-- Launched ketamine clinics in the U.K. and U.S. and expanded treatment options --
https://www.globenewswire.com/news-release/2022/03/08/2398871/0/en/Pasithea-Therapeutics-Announces-Collaboration-with-The-Glimpse-Group.html

https://www.benzinga.com/general/biotech/22/02/25388968/exclusive-pasithea-therapeutics-starts-new-multiple-sclerosis-vaccine-development-program

Weekly SAR @ $2.94 https://stockcharts.com/h-sc/ui?s=ktta&p=W&yr=1&mn=3&dy=0&id=p30814693576

NASDAQ 13.2M O/S https://www.otcmarkets.com/stock/KTTA/security

$52M cash on hand versus $25M market cap. Trading below cash value.

CEO exercised options to add 200k shares at $1.44.

Insiders (34.5%) shares are locked up til March. No risk of dumping.

Average share cost from retail is $4.53.

https://www.pasithea.com

👍️0
$treet $inatra $treet $inatra 2 years ago
Great to see you here bro! $KTTA oversold and will surely test its all time highs $$$$$$$$


https://stockcharts.com/c-sc/sc?s=KTTA&p=W&yr=2&mn=3&dy=0&i=t6030955154c&r=1646760130996
👍️0
ZipCash ZipCash 2 years ago
#KTTA ready to break $2.00 plus

New revs coming and its extreme undervalued here
👍️0
$treet $inatra $treet $inatra 2 years ago
Monster DD https://www.reddit.com/r/pennystocks/comments/sq0wqi/a_penny_stock_that_is_absurdly_undervalued_enough/
👍️0
Aceofspades62 Aceofspades62 3 years ago
Beautifull consolidation…adding heavy here. X5 bagger.
👍️0
FROZENFLAME FROZENFLAME 3 years ago
Adding
$KTTA
👍️0
FROZENFLAME FROZENFLAME 3 years ago
Huge bid !
$KTTA
👍️0
Animas Animas 3 years ago
Nice red to green day. Gap up in morning.
👍️0
Aceofspades62 Aceofspades62 3 years ago
Squeeze imminent. Loaded up here.

KTTA
👍️0
Blutribe Blutribe 3 years ago
OVERSOLD at these levels..I am loading up BIG today!
👍️0
RUSTYJ RUSTYJ 3 years ago
guess it not going hold up?any thoughts
👍️0
PStockPickz PStockPickz 3 years ago
I did then shorted 2.25 solid trades so far
👍️0
$treet $inatra $treet $inatra 3 years ago
$KTTA +55% enjoy the ride up $$$
👍️0
PStockPickz PStockPickz 3 years ago
Adding some 2.06 looks good if it holds over $2
👍️0
PStockPickz PStockPickz 3 years ago
Back up over $2 let's go!
👍️0
$treet $inatra $treet $inatra 3 years ago
bounce time $KTTA $$$ https://finance.yahoo.com/news/pasithea-therapeutics-opens-second-ketamine-130000219.html

https://stockcharts.com/h-sc/ui?s=ktta&p=W&yr=1&mn=3&dy=0&id=p30814693576
https://stockcharts.com/h-sc/ui?s=ktta&p=D&yr=0&mn=3&dy=0&id=p88756283120
👍️0

Your Recent History

Delayed Upgrade Clock